Core Points - Wuhan Huisheng Biotechnology Co., Ltd. has revised its company articles to enhance governance and protect the rights of stakeholders [1][2] - The company was registered on July 27, 2020, and went public on August 24, 2020, with a registered capital of RMB 202.332557 million [1] - The revision includes detailed rules on share management, shareholder rights and obligations, board structure, and management responsibilities [2] Share Management - The total number of shares is 202.332557 million, all of which are ordinary shares [1] - The company has established rules for share issuance, reduction, repurchase, and transfer, ensuring equal rights for the same class of shares [1] - Specific restrictions on share transfer are in place, such as a one-year lock-up period for shares issued before the public offering [1] Shareholder and Shareholder Meeting - The rights and obligations of shareholders, as well as the responsibilities of controlling shareholders and actual controllers, are clearly defined [2] - Shareholders have rights to dividends and participation in shareholder meetings, while also being obligated to comply with the articles and pay share capital [2] - The shareholder meeting has decision-making authority on major company matters, including electing directors and approving profit distribution [2] Board of Directors - The board consists of five directors, including two independent directors and one employee director [2] - The board is accountable to the shareholder meeting and has various powers, including convening meetings and executing resolutions [2] - Detailed responsibilities and operations for independent directors and board committees are outlined [2] Senior Management - The company appoints one general manager and several deputy managers, with clear qualifications and responsibilities for senior management [2] - The articles also cover financial accounting, profit distribution, auditing, and procedures for corporate actions such as mergers and dissolutions [2] Conclusion - The revision of the company articles is a significant step for Huisheng Biotechnology to adapt to its development and market changes, aiming to improve governance and ensure sustainable operations [2]

Group 1 - The company, Huisheng Biological, announced the convening of its third temporary board meeting for the fourth session on October 16, 2025, to discuss the election of committee members [1] - For the fiscal year 2024, the revenue composition of Huisheng Biological is 93.02% from veterinary raw materials and formulations, with the remaining 6.98% from other sources [1] - As of the report date, Huisheng Biological has a market capitalization of 4.2 billion yuan [1]

Group 1 - The company is actively expanding its overseas market presence, with positive sales growth in its international business [2] - The primary component of the overseas business is the export of active pharmaceutical ingredients (APIs), while the formulation export business is still in the exploratory phase [2]

Group 1 - The core point of the article is that Jinhe Biology announced the convening of its 32nd meeting of the sixth board of directors, which reviewed the proposal to amend the internal reporting system for significant matters [1] - For the first half of 2025, Jinhe Biology's revenue composition is as follows: veterinary chemical drugs accounted for 61.83%, agricultural product processing accounted for 19.76%, veterinary biological products accounted for 11.12%, environmental protection business accounted for 4.97%, and others accounted for 2.15% [1] - As of the report date, Jinhe Biology has a market capitalization of 5.4 billion yuan [1]

Group 1 - The core point of the article is that Reap Bio (SZ 300119) held a temporary board meeting on October 13, 2025, to discuss investment proposals with professional investment institutions [1] - For the year 2024, Reap Bio's revenue composition is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chains, and 2.38% from other sources [1] - As of the report date, Reap Bio has a market capitalization of 10.2 billion yuan [1]

Core Viewpoint - Zhongmu Co., Ltd. has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine against Porcine Seneca Virus Disease, marking a significant advancement in the company's product offerings [1] Group 1 - The vaccine is identified as HuN-1/2017 strain and is produced through suspension culture [1] - The company has been issued a New Veterinary Drug Registration Certificate, which is a crucial step for commercialization [1]

Core Viewpoint - Zhongmu Co., Ltd. has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine against Porcine Seneca Virus Disease (HuN-1/2017 strain) as a new veterinary drug [1] Group 1 - The vaccine has been developed in accordance with the "Veterinary Drug Management Regulations" and the "Veterinary Drug Registration Measures" [1] - The approval includes the issuance of a "New Veterinary Drug Registration Certificate" for the product [1]

Core Viewpoint - The approval of "Fluralaner Drops" as a new veterinary drug by the Ministry of Agriculture and Rural Affairs marks a significant development for the company and its subsidiary, enhancing their product portfolio in the veterinary medicine sector [1] Group 1: Regulatory Approval - The Ministry of Agriculture and Rural Affairs has approved the joint application for "Fluralaner Drops" by the company and its wholly-owned subsidiary, Luoyang Huizhong Veterinary Medicine Co., Ltd [1] - The new veterinary drug is set to be officially registered with the issuance of the New Veterinary Drug Registration Certificate on October 11, 2025 [1] Group 2: Indications and Usage - "Fluralaner Drops" is indicated for the treatment of flea (Ctenocephalides felis) and tick (Rhipicephalus sanguineus, Ixodes ricinus) infestations [1] - The product can be used as part of the clinical treatment plan for Flea Allergy Dermatitis (FAD) [1]

Core Viewpoint - The company, Pulaike (603566), has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug, a four-in-one inactivated vaccine for poultry diseases, marking a significant development in the veterinary pharmaceutical industry [1] Group 1: Company Developments - Pulaike and its wholly-owned subsidiary, Luoyang Huizhong Biotechnology Co., Ltd., jointly applied for the new veterinary drug, which includes vaccines for Newcastle disease, infectious bronchitis, avian influenza (H9 subtype), and avian adenovirus disease [1] - The new veterinary drug registration certificate was publicly announced on October 11, indicating successful regulatory approval [1] Group 2: Market Context - As of now, there are no similar four-in-one inactivated vaccine products available for sale in the poultry market, highlighting a potential competitive advantage for the company [1]

Core Viewpoint - The approval of "Fluralaner Drops" as a new veterinary drug by the Ministry of Agriculture and Rural Affairs marks a significant development for the company and its wholly-owned subsidiary, Luoyang Huizhong Veterinary Medicine Co., Ltd, as it addresses a gap in the market for flea and tick treatment in cats [1] Company Summary - The company, 普莱柯 (603566), has received official approval for its new veterinary drug, "Fluralaner Drops," which is intended for the treatment of flea and tick infections in cats [1] - The drug has been registered and the registration certificate was publicly announced on October 11 [1] Industry Summary - As of now, there are no similar products available in the market, indicating a potential competitive advantage for the company in the veterinary pharmaceutical sector [1]